British-based drugmaker GlaxoSmithKline posted a loss of 428 million pounds for the fourth quarter of 2015 - compared with a profit of over 1 billion pounds for the same period a year earlier- as the company moved to integrate new businesses. CEO Andrew Witty said Wednesday the healthcare environment remains challenging, but GSK remained focused on its integration and restructuring program.